Tamoxifen pp 343-358 | Cite as

Antiestrogen Regulation of erbB2 Expression in Human Breast Cancer Cells

  • Anni M. Wärri
  • Pirkko L. Härkönen


The erbB2 protein is supposed to have important functions as a growth factor receptor during growth and differentiation as well as in normal function of the mammary epithelium. It can be activated to a transforming oncogene and in human breast cancer, the amplification and/or overexpression of erbB2 gene is associated with aggressive growth of the tumor and poor prognosis of the patient. The expression of erbB2 is regulated by estrogen and the antiestrogens Tamoxifen and Toremifene which are both used in the treatment of breast cancer. The knowledge of the role and mechanisms of the anti estrogen regulation of this important growth factor receptor and potential oncogene would provide important information of the biology and therapeutic possibilities of human breast cancer.


Breast Cancer Breast Cancer Cell Human Breast Cancer Cell erbB Receptor erbB2 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alper Ö, Yamaguchi K, Hitomi J, Honda S, Matsiushima T, Abe K (1991): The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. Cell Growth Different 1:591–599Google Scholar
  2. Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R (1992): A ligand for the erbB-2 oncogene product (gp 30) induces differentiation of human breast cancer cells. Cell Growth Different 3:401–411Google Scholar
  3. Bargmann CI, Weinberg RA (1988): Increased tyrosine kinase activity associated with the protein encoded by the activatedneu oncogene. Proc Natl Acad Sci USA 85:5394–5398PubMedCrossRefGoogle Scholar
  4. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992): Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 244:85–95CrossRefGoogle Scholar
  5. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Sigurdsson H (1991): ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137–143PubMedGoogle Scholar
  6. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H (1994): ERBB2 amplification is associated with tamoxifen resistence in steroid receptor positive breast cancer. Cancer Lett 81:137–144PubMedCrossRefGoogle Scholar
  7. Bouchard L, Lamarre L, Tremblay PL, Jolicoeur P (1989): Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931–936PubMedCrossRefGoogle Scholar
  8. Breuer B, Luo J-C, DeVivo I, Pincus M, Tatum AH, Daucher J, Minick R, Osborne M, Miller D, Nowak E, Code H, Carney WP, Brandt-Rauf PW: (1993) Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer. Med Sci Res 21:383–384Google Scholar
  9. Carraway III KL, Cantley LC (1994): A new aquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5–8PubMedCrossRefGoogle Scholar
  10. Chen Y, Gill GN (1994): Positive and negative regulatory elements in the human erbB-2 gene promoter. Oncogene 9:2269–2276PubMedGoogle Scholar
  11. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, McGuire WL (1992): Correlation of HER2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84:1279–1282PubMedCrossRefGoogle Scholar
  12. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M (1990): Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001–1006PubMedGoogle Scholar
  13. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987): erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182PubMedCrossRefGoogle Scholar
  14. Dougall WC, Qian X, Peterson NC, Miller M, Samanta A, Greene MI (1994): The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109–2123PubMedGoogle Scholar
  15. Gasparini G, Pozza F, Harris AL (1993): Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206–1219PubMedCrossRefGoogle Scholar
  16. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG (1991): c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434–438PubMedCrossRefGoogle Scholar
  17. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992): Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582PubMedCrossRefGoogle Scholar
  18. Hollywood DP, Hurst HC (1993): A novel transcription factor, OB2–1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12:2369–2375PubMedGoogle Scholar
  19. Hudson LG, Ertl AP, Gill GN (1990): Structure and inducible regulation of the human c-erbB2/neu promoter. J Biol Chem 265:4389–4393PubMedGoogle Scholar
  20. Hudziak RM, Schlessinger J, Ullrich A (1987): Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159–7163PubMedCrossRefGoogle Scholar
  21. Hung M-C, Schechter AL, Chevray P-YM, Stern DF, Weinberg RA (1986): Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci USA 83:261–264PubMedCrossRefGoogle Scholar
  22. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi O-P (1994): Elevated erbB2 oncoprotein levels in pre-operative and follow-up serum samples define breast cancer patients with aggressive disease course. Cancer 3:652–658CrossRefGoogle Scholar
  23. Johnston SRD, McLennan KA, Salter J, Sacks NM, McKinna JA, Baum M, Smith IE, Dowsett M (1993): Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in-vivo. The Breast 2:93–99Google Scholar
  24. Jordan VC, Murphy CS (1990): Endocrine pharmacology of antiestrogens as antitumor agents. Endoer Rev 11:578–610CrossRefGoogle Scholar
  25. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Piippo I, Sundquist H, Södervall M, Toivola R (1986): A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 17:103–108PubMedCrossRefGoogle Scholar
  26. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH and Isola JJ (1993): Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650–655CrossRefGoogle Scholar
  27. Kallioniemi O-P, Kallioniemi A, Kurisu W, Thor A, Chen L-C, Smith HS, Waldman, FM, Pinkel D, Gray, JW (1992): ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321–5325PubMedCrossRefGoogle Scholar
  28. Kangas L, Nieminen A-L, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perila M, Södervall M, Toivola R (1986): A new triphenylethylene compound, Fc-1157a. II. Antitumor effect. Cancer Chemother Pharmacol 17:109–113PubMedCrossRefGoogle Scholar
  29. Koskinen P, Lehväslaiho H, MacDonald-Bravo H, Alitalo K, Bravo R (1990): Similar early responses to ligand-activated EGFR andneu tyrosine kinases in NIH3T3 cells. Oncogene 5:615–618PubMedGoogle Scholar
  30. Kraus MH, Fedi P, Starks V, Muraro R and Aaronson SA (1993): Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90:2900–2904PubMedCrossRefGoogle Scholar
  31. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE (1991): An antigen immunologically related to the extracellular domain of gp185 in shed from nude mouse tumors over-expressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 51:2593–2598PubMedGoogle Scholar
  32. Lehväslaiho H, Lehtola L, Sistonen L, Alitalo KA (1989): Chimeric EGF-R/neu proto-oncogene allows to regulate neu tyrosine kinase and cell transformation. EMBO J 8:159–166PubMedGoogle Scholar
  33. Leitzel K, Teramoto Y, Sampson EL, Wallingford GA, Weaver S, Domero L, Harvey H, Lipton A (1991): Elevatedc-erbB-2 levels in the serum and tumor extracts of breast cancer patients. Proc Am Assoc Cancer Res 32:997–1005Google Scholar
  34. Lin YJ and Clinton GM (1991): A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6:639–643PubMedGoogle Scholar
  35. Marchionni MA, Goodearl ADJ, Che MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kovayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty N, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D (1993): Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312–318PubMedCrossRefGoogle Scholar
  36. Marte BM, Jeschke M, Graus-Porta D, Taveraa D, Hofer P, Groner B, Yarden Y, Hynes NE (1995): Neu differentiation factor/heregulin modulates growth and differentiation of HC 11 mammary epithelial cells. Mol Endocrinol 9:14–23PubMedCrossRefGoogle Scholar
  37. Meyer D and Birchmeier C (1994): Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc Natl Acad Sci USA 91:1064–1068PubMedCrossRefGoogle Scholar
  38. Müller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988): Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115PubMedCrossRefGoogle Scholar
  39. Pasleau F, Grooteclaes M, Gol-Winkler R (1993): Expression of the c-erbB2 gene in the Bt-474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 8:849–85PubMedGoogle Scholar
  40. Peles E and Yarden Y (1993): Neu and its ligands: from an oncogene to neural factors. BioEssays 15:815–824Google Scholar
  41. Perren TJ (1991): c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328–332PubMedCrossRefGoogle Scholar
  42. Philips A, Chalbos D, Rochefort H (1993): Estradiol increases and antiestrogens antagonize the growth factor-induced Activator Protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268:14103–14108PubMedGoogle Scholar
  43. Pierce JH, Arnheim P, DiMarco E, Artrip J, Kraus MH, Lonardo F (1991): Oncogenic potential of erbB2 in human mammary epithelial cells. Oncogene 6:1189–1194PubMedGoogle Scholar
  44. Plowman GD, Culouscou J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M (1993): Ligand-specific activation of HER-4/p180Berb B4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746–1750PubMedCrossRefGoogle Scholar
  45. Prigent SA, Lemoine NR (1992): The type 1 (EGFR-related) family of growth factor receptors and their ligands. Progr Growth Factor Res 4:1–24CrossRefGoogle Scholar
  46. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS (1990): Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947–3951PubMedGoogle Scholar
  47. Rüssel KS, Hung M-C (1992): Transcriptional repression of the neu proto-oncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624–6629Google Scholar
  48. Scott GK, Robels R, Park JW, Montgomery PA, Daniel J, Holmes WE, Keller GA, Li W-L, Fendly BM, Wood WI, Shepard M, Benz CC (1993): A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13:2247–2257PubMedGoogle Scholar
  49. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987): Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  50. Slamon DJ Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989): Studies of the HER-2Ineu proto-oncogene in human breast and ovarian cancer. Science 244:707–712CrossRefGoogle Scholar
  51. Stein D, Wu J, Fuqua SAW, Roonprapunt C, Yajnik V, D’Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B (1994): The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 13:6:1331–1340PubMedGoogle Scholar
  52. Stern DF, Kamps MP, Cao H (1988): Oncogenic activation of pp180neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969–3973PubMedGoogle Scholar
  53. Taverna D, Groner B, Hynes NE (1991): Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation. Cell Growth Different 2:145–154Google Scholar
  54. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE (1994): erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56:522–528Google Scholar
  55. Ullrich A, Schlessinger J (1990): Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212PubMedCrossRefGoogle Scholar
  56. Van de Vijver MJ, Nusse R (1991): The molecular biology of breast cancer. Biochim Biophys Acta 1072:35–50Google Scholar
  57. Wärri AM, Laine AM, Majasuo KE, Alitalo KK, Härkonen PL (1991): Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR 75–1 human breast cancer cells in vitro and in nude mice. Int J Cancer 49:616–623PubMedCrossRefGoogle Scholar
  58. Wärri AM (1993): Toremifene-induced regression in breast cancer. Cellular and molecular mechanisms. Academic Dissertation. University of Turku, Turku, FinlandGoogle Scholar
  59. Wärri AM, Isola JJ, Härkonen PL (1994): Estrogen and antiestrogen regulation of amplified erbB2 gene expression in human cancer cells. In: Hormonal Carcinogenesis, 2nd Ed., J.J. Li, S. Nandi and S.A. Li (Eds) Springer-VerlagGoogle Scholar
  60. Wärri AM, Isola JJ, Härkonen PL (1995): Antiestrogen stimulation of erbB2 ectodomain shedding from BT-474 human breast cancer cells with erbB2 gene amplification. Eur J Cancer (In Press)Google Scholar
  61. Webb P, Lopez GN, Uht RM, Kushner PJ (1995): Tamoxifen activation of the estrogen receptor/AP-i pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443–456PubMedCrossRefGoogle Scholar
  62. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Home CHW (1992): Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118–121PubMedCrossRefGoogle Scholar
  63. Zabrecky JR, Lam T, McKenzie SJ, Carney, W (1991): The extracellular domain of p185neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716–1720PubMedGoogle Scholar

Copyright information

© Birkhäuser Boston 1996

Authors and Affiliations

  • Anni M. Wärri
  • Pirkko L. Härkönen

There are no affiliations available

Personalised recommendations